Literature DB >> 6226944

A procedure for isolation of human protein C and protein S as by-products of the purification of factors VII, IX, X and prothrombin.

S P Bajaj, S I Rapaport, S L Maki, S F Brown.   

Abstract

A DEAE-Sephadex column chromatography step utilized to purify human Factor VII consistently yields a protein peak between the factor VII activity peak and prothrombin, factor X and factor IX activity peak (S.P. Bajaj, S.I. Rapaport, and S.F. Brown: J. Biol. Chem. 251, 253-259, 1981). We now report that this protein peak contains protein C and protein S. Preparative disc polyacrylamide gel electrophoresis of the proteins in this peak permitted a complete separation of protein C from protein S. Protein C at this step usually contained approximately 5-10% of Factor X, which could be removed by a goat anti-human Factor X antibody column. For a typical preparation, starting with 10L of plasma, the yield of Protein C was 5 mg and of protein S was 4 mg. Both proteins revealed apparent homogeneity in sodium dodecyl sulfate gel electrophoretic system. beta-Protein C and beta-protein S were not observed in our preparations starting with plasma collected directly into citrate anticoagulant containing benzamidine and soybean trypsin inhibitor, suggesting that these beta forms of protein C and protein S, isolated by other investigators, are slightly degraded forms of the native proteins. Antisera generated to these proteins were monospecific and could be used to monitor column fractions during purification. When examined by immunoelectrophoresis, the electrophoretic mobility of protein S in plasma was slower than that of isolated protein S. When exposed to plasmin, protein C was activated slightly and then rapidly degraded.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6226944     DOI: 10.1080/00327488308064248

Source DB:  PubMed          Journal:  Prep Biochem        ISSN: 0032-7484


  8 in total

1.  Mapping through somatic cell hybrids and cDNA probes of protein C to chromosome 2, factor X to chromosome 13, and alpha 1-acid glycoprotein to chromosome 9.

Authors:  M Rocchi; L Roncuzzi; R Santamaria; N Archidiacono; L Dente; G Romeo
Journal:  Hum Genet       Date:  1986-09       Impact factor: 4.132

2.  Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation.

Authors:  L V Rao; S I Rapaport
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

3.  Inhibitor of the factor VIIa-tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease.

Authors:  M S Bajaj; S V Rana; R B Wysolmerski; S P Bajaj
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

4.  Zn²(+) -containing protein S inhibits extrinsic factor X-activating complex independently of tissue factor pathway inhibitor.

Authors:  N Fernandes; L O Mosnier; L Tonnu; M J Heeb
Journal:  J Thromb Haemost       Date:  2010-09       Impact factor: 5.824

5.  Human platelets contain and secrete osteonectin, a major protein of mineralized bone.

Authors:  D D Stenner; R P Tracy; B L Riggs; K G Mann
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

6.  Differences in prethrombin-1 activation with human or bovine factor Va can be attributed to the heavy chain.

Authors:  Paul Y Kim; Reginald Manuel; Michael E Nesheim
Journal:  Thromb Haemost       Date:  2009-10       Impact factor: 5.249

7.  Plasma protein S contains zinc essential for efficient activated protein C-independent anticoagulant activity and binding to factor Xa, but not for efficient binding to tissue factor pathway inhibitor.

Authors:  Mary J Heeb; Duane Prashun; John H Griffin; Bonno N Bouma
Journal:  FASEB J       Date:  2009-02-24       Impact factor: 5.191

8.  Fibulin-1 purification from human plasma using affinity chromatography on Factor H-Sepharose.

Authors:  Richard G DiScipio; Robert C Liddington; Ingrid U Schraufstatter
Journal:  Protein Expr Purif       Date:  2016-01-28       Impact factor: 1.650

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.